Program
Doxorubicin
Also written as “doxorubicin hydrochloride”, “Doxorubicin hydrochloride (liposomal)” and “doxorubicin”.
Its studies are mostly in Breast Neoplasms · Sarcoma · Lymphoma, Large B-Cell, Diffuse · Carcinoma, Hepatocellular · Sarcoma, Kaposi, led by 16 companies.
Drug pageDoxorubicin: every studyMany companies study it; this page follows only the 34 they lead. All 779 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 50 open or running | phase 2since Jan 25, 2005 | Jan 25, 2005 | none ahead |
| Johnson & Johnson | 40 open or running | phase 3since Feb 9, 2005 | Jan 31, 2005 | none ahead |
| Sanofiits history only | 40 open or running | phase 3since Jul 11, 2001 | Jul 11, 2001 | none ahead |
| Sequus Pharmaceuticalsits history only | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Amgenits history only | 30 open or running | phase 3since Mar 31, 2003 | Jul 5, 2000 | none ahead |
| InSightecits history only | 22 open or running | phase 2since Nov 7, 2022 | Nov 7, 2022 | none ahead |
| Philogenits history only | 20 open or running | phase 2since May 25, 2010 | May 25, 2010 | none ahead |
| Teva Pharmaceutical Industriesits history only | 20 open or running | phase 2since Oct 24, 2005 | Oct 24, 2005 | none ahead |
| Alfacellits history only | 10 open or running | phase 3since Nov 1, 1999 | Nov 1, 1999 | none ahead |
| Bio-Cancer Treatment Internationalits history only | 10 open or running | phase 1since Sep 30, 2009 | Sep 30, 2009 | none ahead |
| Presage Biosciencesits history only | 10 open or running | phase 1since Jan 22, 2017 | Jan 22, 2017 | none ahead |
| Sopherion Therapeuticsits history only | 10 open or running | phase 3since Feb 17, 2006 | Feb 17, 2006 | none ahead |
| Spirovant Sciencesits history only | 11 open or running | phase 2since Jul 18, 2024 | Jul 18, 2024 | Dec 31, 2026phase 2 · NCT06526923 |
| Sutphin Drugsits history only | 10 open or running | early phase 1since Jun 3, 2019 | Jun 3, 2019 | none ahead |
| Valerio Therapeuticsits history only | 10 open or running | phase 3since Jul 26, 2012 | Jul 26, 2012 | none ahead |
| Zivenaits history only | 10 open or running | phase 2since May 11, 2004 | May 11, 2004 | none ahead |
Also a collaborator on its studies: AbbVie and PharmaMar.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Johnson & Johnson only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 31, 2005First study: phase 1 study in SarcomaFirst studyNCT00102609 · 41 enrolled
- Feb 9, 2005Phase 3 study in Multiple MyelomaNCT00103506 · 646 enrolled · United States, Argentina, Australia and more
- Sep 13, 2005Phase 2 study in Ovarian NeoplasmsNCT00216645 · 74 enrolled
- Mar 14, 2013Phase 1 study in NeoplasmsNCT01815294 · 54 enrolled · United States, Belgium, Spain and more
TargetBeta
“DNA topoisomerase II alpha inhibitor; DNA inhibitor”ChEMBL 37, by rule
Other programs on TOP2A
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Etoposiderule | Hoffmann-La Roche | phase 3 | 28 |
| amrubicinrule | Bristol-Myers Squibb | phase 3 | 9 |
| Daunorubicinrule | kura-oncology-inc | phase 3 | 7 |
Studies
All 4 Johnson & Johnson leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01815294Neoplasms · United States, Belgium, Spain and more | 1 | Completed | Dec 2014 | 54 |
| NCT00216645Ovarian Neoplasms | 2 | Completed | 74 | |
| NCT00103506Multiple Myeloma · United States, Argentina, Australia and more | 3 | Completed | May 2014 | 646 |
| NCT00102609Sarcoma | 1 | Completed | 41 |
How it is read
Names in the registry
- “Doxorubicin”, 29 entries
- “doxorubicin hydrochloride”, 6 entries
- “Doxorubicin hydrochloride (liposomal)”, 4 entries
- “doxorubicin”, 3 entries
- “CHOP”, 2 entries
Conditions, from the studies’ own filings
- Breast Neoplasms, 15 studies
- Sarcoma, 8 studies
- Lymphoma, Large B-Cell, Diffuse, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Sarcoma, Kaposi, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.